Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Transformative New System Brings Whole Genome Sequencing to the Desktop

By BiotechDaily International staff writers
Posted on 30 Jan 2014
Image: The NextSeq 500 System from Illumina, capable of sequencing a whole human genome in a single run, delivers the power of high-throughput sequencing with the simplicity of a desktop sequencer (Photo courtesy of Illumina).
Image: The NextSeq 500 System from Illumina, capable of sequencing a whole human genome in a single run, delivers the power of high-throughput sequencing with the simplicity of a desktop sequencer (Photo courtesy of Illumina).
A new sequencer transforms high-throughput performance into an affordable desktop form factor, enabling users to perform applications more quickly and conveniently.

Illumina (San Diego, CA, USA) now adds the NextSeq 500 System to its next-generation sequencing (NGS) portfolio. The NextSeq 500 System, currently priced at USD 250,000, delivers the flexible power of high-throughput sequencing with the load-and-go simplicity of a desktop sequencer, effectively transforming a broad range of high-throughput applications into affordable, everyday research tools.

“Illumina’s sequencing portfolio is the most comprehensive in the world, and the addition of the NextSeq 500 System furthers this distinction by enabling next-generation sequencing to become an everyday tool,” said Jay Flatley, CEO, Illumina; “The NextSeq 500 was reimagined from the ground up and uses technology breakthroughs in optics, fluidics and chemistry to bring high throughput power to the desktop at a significantly reduced cost.”

Its push-button operation delivers a one-day turnaround for several sequencing applications, including one whole human genome and up to 16 exomes, up to 20 noninvasive prenatal testing samples, up to 20 transcriptomes, up to 48 gene expression samples and up to 96 targeted panels. With its streamlined informatics, sequencing data can be run through a range of open source or commercial pipelines, or instantly transferred, analyzed, and stored securely in "BaseSpace,” or in the new "BaseSpace OnSite" for researchers needing an on premises solution.

Users also have the flexibility to switch to lower throughput sequencing as needed, and while other platforms require several pieces of specialized equipment, the NextSeq 500 System integrates cluster generation and sequencing into a single instrument. Data is generated in as little as 12 hours for a 75-cycle sequencing run and less than 30 hours for paired 150-cycle reads. The new system is supported by the full suite of Illumina sample preparation and target enrichment solutions, offering library compatibility across the entire Illumina sequencing portfolio. Its configurable output supports a wide range of applications and sample sizes with the accuracy of Illumina sequencing-by-synthesis (SBS) technology.

Related Links:

Illumina



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.